CD4+CD25int/highCD127low 调节性T细胞在再生障碍性贫血患儿中的检测及意义

目的：探讨再生障碍性贫血（AA）患儿外周血 CD4+ CD25int/high CD127low 调节性 T 细胞（Treg）的表达特点及其与 Hb、WBC 和 血小板（Plt）数量的相关性。方法：采用流式细胞术检测 15 例正常儿童（对照组）和 22 例治疗有效的AA患儿治疗前后外周血 CD4+ CD25int/high CD127low Treg百分比的变化，分析 CD4+CD25high-CD127low Treg与 Hb、WBC 和 Plt 数量的相关性。结果：AA 组急性期外周血 CD4+CD25+、CD4+CD25high、CD4+CD25+CD127low、CD4+CD25highCD127low Treg占 CD4+ T 细胞的百分比均较对照组显著降低（P﹤0.05）；恢复期的表达则高于急性期（P﹤0.05），而与对照组比较差异无统计学意义（P﹥0.05）。AA组急性期、恢复期及对照组的 CD4+CD25highCD127low Treg表达率与外周血中 Hb、WBC 和 Plt 数量均呈正相关（r分别为 0.499、0.526、0.540，P<0.05）。结论：CD4+CD25int/highCD127low Treg 减低可能与 AA 发病有关，为其作为判断 AA 病情变化的指标提供了可能的理论依据，并可以作为免疫治疗的靶点之一进行深入研究。

Detection and significance of CD4+ CD25int/high CD127low regulatory T cells in pediatric aplastic anemia

Objective To study the expression of CD4+ CD25int/high CD127low regulatory T cells in peripheral blood(PB) and its relation to the quantity of Hb,WBC and platelet(Plt) in children with aplastic anemia(AA).Methods Expression of CD4+ CD25int/high CD127low in PB was detected by flow cytometry in 22 children with AA before and after treatment and in 15 healthy controls.The relationships between CD4+CD25highCD127low and the quantity of Hb,WBC and Plt were evaluated.Results Compared to controls,the percentages of CD4+ CD25+/CD4+,CD4+CD25high/CD4+,CD4+ CD25+ CD127low/CD4+ and CD4+CD25highCD127low/CD4+ in PB of AA patients decreased markedly at the active phase(P﹤0.05).By the recovery phase,the percentages of CD4+CD25+/CD4+,CD4+CD25high/CD4+,CD4+ CD25+ CD127low/CD4+ and CD4+CD25highCD127low/CD4+ increased significantly to the levels similar to the controls.There were significant positive relationships between the expression of CD4+CD25highCD127low cells and the quantity of Hb,WBC and Plt(r=0.499,0.526,0.540 respectively;P﹤0.05).Conclusions The decrease of the percentage of CD4+CD25int/highCD127low regulatory T cells might be associated with the development of pediatric AA.The CD4+CD25int/highCD127low regulatory T cells can serve as a marker for the evaluation of disease severity as well as a target of further study on immune treatment of AA.